Capricor’s $150M stock sale

In today’s episode of Breaking News to Trading Moves we look at Capricor Therapeutics after the company followed up its huge Duchenne muscular dystrophy rally with a fresh 150 million dollar stock offering. Capricor is selling 6 million shares of common stock at 25 dollars a share, with an option for another 900 thousand shares. The money goes into pushing its late stage DMD cell therapy Deramiocel and its exosome platform further down the road.

Winners

Clinical research and outsourcing platforms

Names: $ICLR, $IQV

Reason: A fully funded Capricor pipeline means more late-stage trial work, data management and real-world evidence projects. Global contract research and analytics players such as ICON and IQVIA tend to benefit whenever clinical stage biotechs raise large su ...